[182 Pages Report] The Albumin Market size was estimated at USD 6.53 billion in 2023 and expected to reach USD 6.94 billion in 2024, at a CAGR 6.61% to reach USD 10.23 billion by 2030.

Albumin is a complex and versatile protein that constitutes approximately 50%-60% of the total protein content in human blood plasma. It is synthesized predominantly by the liver and plays an essential role in physiological functions, such as maintaining osmotic pressure, binding and transporting various molecules, and acting as an antioxidant. Albumin's importance lies in its multifaceted contributions to overall health and well-being, making it a significant biomarker for assessing an individual's disease risk and clinical status. The growing usage of albumin in clinical settings for the treatment of burns and the rising prevalence of liver diseases where patients require a regular supply of HSA to maintain proper health functions has accelerated the use of albumin worldwide. However, risks associated with contamination and transmission of infectious agents in HSA products sourced from pooled human plasma donations impact albumin usage. Stringent regulatory guidelines for product approvals in different regions also affect the commercialization of albumin. Market players are investing in research and development initiatives that explore innovative production methods, such as plant-based expression systems or microbial fermentation processes capable of yielding high-quality albumin products at lower costs. New opportunities are emerging with the evolution of biotechnological advancements that enable the production of recombinant human albumins (rHA) through genetic engineering techniques.

The Americas albumin market is advancing, driven by investments by pharmaceutical companies investing heavily in research and technology to develop advanced albumin formulations. Regulatory bodies such as the Food and Drug Administration (FDA) in the U.S. enforce strict quality control measures to assure safety standards of albumin. The FDA has also given approval for certain albumin products in recent years. Technological advancements such as recombinant HSA production are being researched across the U.S. and Canada to potentially reduce dependency on human plasma donations for albumin supply. The Asian albumin market is experiencing rapid expansion fueled by increasing healthcare expenditure and improving medical infrastructure in emerging countries demanding plasma-derived products for therapeutic purposes, including liver disease treatment, surgeries, and intensive care support. Europe is a potential contributor to the global albumin market, with an established consumption base and robust manufacturing capabilities. The use of albumin in Europe is primarily focused on critical care applications such as sepsis management, volume replacement therapies, and therapeutic plasma exchange procedures. The European Medicines Agency (EMA) regulates the production and distribution of albumin within the European Union (EU).

The market dynamics represent an ever-changing landscape of the Albumin Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

• Market Drivers
  • Incidence of chronic diseases and use of albumin as a predictor of postoperative surgical site infections
  • Surging utilization of albumin as a food and cosmetic ingredient
• Market Restraints
  • Potential of albumin to cause transmission of infections
• Market Opportunities
  • Ongoing research activities regarding albumin nanoparticles
  • Advancements in albumin production and purification methods
• Market Challenges
  • Stringent regulations associated with albumin manufacturing and quality control

• Source: Consumer shift toward the plant-based albumins due to enhanced sustainability for specific therapeutic purposes.

  Albumin, an important protein in the blood, plays essential role in maintaining fluid balance and transporting hormones, fatty acids, and drugs. The two primary albumin sources are animal-based and plant-based. Animal-derived albumin is obtained from bovine serum (BSA), human plasma (HSA), and ovalbumin. Bovine serum albumin (BSA) is a vital ingredient in various applications, such as diagnostic reagents, vaccines, and cell culture media. BSA is widely utilized in diagnostics and research due to its affordability and accessibility. Human serum albumin (HSA) is preferred for certain clinical situations, such as drug delivery systems or volume expansion therapies, due to its biocompatibility with humans. HSA is used in medical emergencies such as burns treatment and cardiopulmonary bypass surgery. In recent years, plant-based alternatives have emerged as a sustainable option for albumin production due to their reduced environmental impact and potential allergen risks. Plant-derived albumins, including rice and soy protein, are gaining popularity as alternatives to animal-derived counterparts for applications in food & beverage production, pharmaceuticals, and cosmetics. Comparatively, animal-derived albumins have established medical applications, although they pose a risk of disease transmission. In contrast, plant-based albumins offer sustainability with minimal contamination risk but may lack compatibility for specific therapeutic purposes. However, consumer trends to preferences to choose products between animal or plant-based albumins depend on factors such as application purpose, purity requirements, sustainability concerns, and potential risks associated with animal proteins.

• Type: Enhanced emphasis on the research and development of recombinant albumin as a synthetic protein to promote recombinant DNA technology

  Non-recombinant albumin is derived from natural sources, primarily human and bovine serum. It is widely used in pharmaceutical formulations, diagnostics, cell culture media, and medical devices due to its stabilizing properties for proteins and enzymes. The need-based preference for non-recombinant albumin arises from its availability in large quantities as a byproduct of blood fractionation processes. Recombinant albumin is produced using genetically engineered expression systems such as yeast and mammalian cells. It eliminates the risk of contamination with pathogens and offers a more consistent and sustainable supply compared to non-recombinant albumin. Recombinant albumin is mainly used in drug delivery systems, vaccines, cell therapy applications, and regenerative medicine. The preference for recombinant albumin is driven by its safety profile, as it is free from human or animal-derived components which may carry potential risks of transmitting infectious agents.

• Application: Rising focus on vaccine manufacturing and drug delivery applications

  Albumin is widely used as a cosmetic ingredient due to its excellent water-binding properties, enhancing skin hydration and elasticity. In the biotechnology industry, albumin serves as an essential component of culture media to support cell growth and proliferation. Albumin's drug delivery application capitalizes on its ability to bind various molecules while maintaining stability in different conditions. Albumin is employed in various products as a food ingredient due to its functional properties, such as emulsification and foaming. Albumin-based therapeutics are employed in treatments for conditions such as hypoalbuminemia and burns. Moreover, vaccine manufacturers use albumins as stabilizers or preservatives to enhance vaccine stability during storage and transportation.

• End-User: Extensive end-users of the albumin in hospitals and blood banks

  The major end-users of albumin can be categorized into primary sectors including, hospitals & clinics, pharmaceutical & biotechnology companies, academic research institutes, and blood banks. These establishments utilize albumin products for various purposes such as drug formulation, diagnostics, vaccine manufacturing, clinical nutrition support, cell culture growth media supplementation, and blood volume expansion. In hospitals & clinics Albumin is often employed to treat patients suffering from hypoalbuminemia – a condition characterized by low levels of albumin in the blood – caused by critical illness or injury. Additionally, it is utilized for fluid resuscitation during surgeries or trauma cases where blood loss has occurred. In recent years, albumin has also gained popularity as a component of parenteral nutrition formulas providing essential proteins needed for patients who are unable to consume food orally. Moreover, blood banks utilize it as a plasma expander to increase blood volume in patients undergoing blood transfusion or those with severe blood loss due to trauma, surgery, or other conditions. Albumin solutions can help maintain osmotic pressure, stabilize hemodynamic parameters, and improve overall circulatory function during such critical situations.

The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the Albumin Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the Albumin Market.

The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Albumin Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.

The value chain of the Albumin Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.

The pricing analysis comprehensively evaluates how a product or service is priced within the Albumin Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the Albumin Market.

The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the Albumin Market.

The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the Albumin Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.

The trade analysis of the Albumin Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.

The regulatory framework analysis for the Albumin Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Albumin Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Albumin Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

• Grifols Completes Enrollment In Phase 3 Study Of Long-Term Albutein (Albumin-Human Injection) Therapy For Patients With Decompensated Cirrhosis

  Grifols SA has completed enrollment in the PRECIOSA Phase 3 trial, which aims to evaluate the potential of long-term albumin treatment with Albutein in increasing the survival time of patients with decompensated cirrhosis and ascites. Albumin exhibits antioxidant and anti-inflammatory properties that could help alleviate complications associated with decompensated cirrhosis, ultimately reducing mortality rates for this condition. [Published On: 2023-07-18]

• Kedrion's Global Portfolio Expands To China To Supply Human Albumin

  Kedrion Biopharma, an international biopharmaceutical company, announced the approval of its human Albumin product for release in the Chinese market. This approval is a significant milestone for the company, as it marks the first-ever biopharmaceutical product to be approved in China. It enables Kedrion to regularly ship its products to the country, meeting the substantial demand from China. [Published On: 2023-07-12]

• GC Biopharma inks USD 90mn deal for blood products in Brazil

  GC Biopharma Co. has entered into a five-year supply agreement with Blau Farmacêutica, a Brazilian pharmaceutical company, to provide its IVIG-SN 5% blood product, valued at USD 90.48 million. This partnership with Blau Farmacêutica represents a significant opportunity for GC Biopharma to expand its global market share and further contribute to the healthcare industry. [Published On: 2023-07-03]

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Albumin Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

The report delves into recent significant developments in the Albumin Market, highlighting leading vendors and their innovative profiles. These include Rockland Immunochemicals Inc., VitroScient, Serion GmbH, Kraeber & Co. GmbH, Promega Corporation, Rocky Mountain Biologicals, LLC, CENTURION PHARMA İlaç Sanayi ve Ticaret A.Ş., Glentham Life Sciences Limited, GC Biopharma Corp., Octapharma AG, F. Hoffmann-La Roche AG, Bio Products Laboratory Ltd., LGC Science Group Holdings Limited, Bio-Rad Laboratories, Inc., Biorbyt Ltd., Kedrion S.p.A, Lazuline Biotech Private Limited, Boston BioProducts Inc., Bristol-Myers Squibb Company, Merck KGaA, Agilent Technologies, Inc., Dem İlaç, Biogenix Inc. Pvt. Ltd., Biowest SAS, SK Plasma, CSL Limited, Midas Pharma GmbH, China Biologic Products Holdings, Inc. by Taibang Biologic Group, Aadi Bioscience, Inc., Avantor Inc., Thermo Fisher Scientific Inc., Prospec-Tany Technogene Ltd., Bio-Techne Corporation, Becton, Dickinson and Company, Atlantis Bioscience Pte Ltd., Baxter International Inc., Akron Biotech, InVitria, Biophyll GmbH, Takeda Pharmaceuticals Company Limited, Sartorius AG, Grifols SA, Ventria Bioscience Inc., and InVitroCare Inc..

This research report categorizes the Albumin Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Source
  • Animal Sources
    • Bovine Serum Albumin
    • Human Serum Albumin
    • Ovalbumin
  • Plant Sources
• Type
  • Non-Recombinant
  • Recombinant
• Application
  • Cosmetic Ingredient
  • Culture Media
  • Drug Delivery
  • Food Ingredient
  • Therapeutic
  • Vaccine Ingredient
• End User
  • Pharmaceutical & Biotechnology
  • Research Institutes

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

1. What is the current market size and projected growth?
2. Which products, segments, applications, and regions offer promising investment opportunities?
3. What are the prevailing technology trends and regulatory frameworks?
4. What is the market share and positioning of the leading vendors?
5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?